Showing 1 - 10 of 11
Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of...
Persistent link: https://www.econbiz.de/10012464639
The estimates indicate that cancer sites about which more research-supported articles were published since the 1970s had larger reductions in premature mortality and hospitalization during the period 1999-2013, controlling for the change in the number of people diagnosed. Cancer sites for which...
Persistent link: https://www.econbiz.de/10012455440
I analyze the effects of four types of medical innovation and cancer incidence on U.S. cancer mortality rates during …Under the assumption that there were no pre-dated factors that drove both innovation and mortality and that there would … have been parallel trends in mortality in the absence of innovation, the estimates indicate that there were three major …
Persistent link: https://www.econbiz.de/10012462770
We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to …
Persistent link: https://www.econbiz.de/10012464638
the elasticity of innovation with respect to the expected price of drugs should be at least as great as the elasticity of … innovation with respect to expected market size (disease incidence). I examine the cross-sectional relationship between … pharmaceutical innovation and market size among a set of diseases (different types of cancer) exhibiting substantial exogenous …
Persistent link: https://www.econbiz.de/10012466126
higher rates of lab and outpatient innovation had greater declines in the probability of missing work during 1996-2003. This … for initial disability, the inverse relationship between lab innovation and disability changes disappears. This is because … there is a significant inverse relationship between initial health and the extent of laboratory innovation. But due to …
Persistent link: https://www.econbiz.de/10012466549
We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Our data cover virtually all of the diseases borne by people in 52 countries during the period 1982-2001, and enable us to...
Persistent link: https://www.econbiz.de/10012468944
We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …
Persistent link: https://www.econbiz.de/10012472240
This paper presents an econometric analysis of the effect of changes in the quantity and type of pharmaceuticals prescribed by physicians in outpatient visits on rates of hospitalization, surgical procedure, mortality, and related variables. It examines the statistical relationship across...
Persistent link: https://www.econbiz.de/10012473446
of decline across cancer sites. I analyze the effect that pharmaceutical innovation had on premature cancer mortality in … Canada during the period 2000-2011, by investigating whether the cancer sites that experienced more pharmaceutical innovation …The estimates imply that pharmaceutical innovation during the period 1985-1996 reduced the number of years of potential …
Persistent link: https://www.econbiz.de/10012457428